关键词： 艾尔健 SkinMedica
2012年12月24日讯 /生物谷BIOON/ --艾尔健(Allergan)宣布，已完成对SkinMedica公司局部美学（ topical aesthetics）皮肤护理业务的收购，包括各种“医生配发（physician despensed）”的非处方美学护肤品及处方产品。此次收购耗资3.5亿美元，Allergan计划将SkinMedica作为一个独立的全球性业务进行运作，同时将充分利用Allergan现有的首选客户程序及SkinMedica产品线。（生物谷bioon.com）
英文原文：
ViiV Healthcare today announced the submission of regulatory applications in the European Union (EU), United States (US) and Canada for the investigational integrase inhibitor dolutegravir (S/GSK1349572) for the treatment of HIV infection in adults and adolescents, specifically:
A Marketing Authorisation Application to the European Medicines Agency for dolutegravir for the treatment of HIV infection in adults and children aged 12 years and older.
A New Drug Application to the US Food and Drug Administration for dolutegravir for the treatment of HIV infection in adults and children aged 12 years and older.
A New Drug Submission to Health Canada for dolutegravir for the treatment of HIV infection in adults and children aged 12 years and older.
"These regulatory submissions are an important step for ViiV Healthcare, representing our commitment as a company to bring new treatments to people living with HIV." said John Pottage, MD, Chief Scientific and Medical Officer, ViiV Healthcare. "We are encouraged by the comprehensive data package supporting dolutegravir, and believe that it has the potential to offer an important new option for the treatment of both naïve and treatment-experienced patients with HIV."
